ING1 represses transcription by direct DNA binding and through effects on p53

Cancer Research

Volumn 63, Issue 18, 2003, Pages 5785-5792

  Kataoka, Hiromi ^a   Bonnefin, Paul ^a   Vieyra, Diego ^a   Feng, Xiaolan ^a   Hara, Yasuo ^a   Miura, Yutaka ^b   Joh, Takashi ^b   Nakabayashi, Hidekazu ^c   Vaziri, Homayoun ^d   Harris, Curtis C ^e   Riabowol, Karl ^a,f  

^a UNIVERSITY OF CALGARY   (Canada)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^c HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e NATIONAL CANCER INSTITUTE   (United States)

^f #370 HMRB ^*  (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; ING1 PROTEIN; ING2 PROTEIN; ISOPROTEIN; LYSINE; NUCLEAR FACTOR I; PROTEIN; PROTEIN P21; PROTEIN P33 ING1B; PROTEIN P47 ING1A; PROTEIN P47 ING3; PROTEIN P53; UNCLASSIFIED DRUG;

ACETYLATION; APOPTOSIS; ARTICLE; CELL CYCLE; CELL LINE; CELL TYPE; COMPLEX FORMATION; CONTROLLED STUDY; DEACETYLATION; DNA BINDING; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN INTERACTION; PROTEIN MOTIF; SENESCENCE; TRANSCRIPTION REGULATION;

ACETYLATION; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DNA, NEOPLASM; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HCT116 CELLS; HISTONE DEACETYLASES; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER NEOPLASMS; LYSINE; NUCLEAR PROTEINS; PLASMIDS; PROMOTER REGIONS (GENETICS); PROTEIN BINDING; PROTEINS; SIRTUINS; TRANSCRIPTION, GENETIC; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 0141731318     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Garkavtsev, I., Kazarov, A., Gudkov, A., and Riabowol, K. Suppression of the novel growth inhibitor p33ING1 promotes neoplastic transformation. Nat. Genet., 14: 415-420, 1996.
2. Sager, R. Expression genetics in cancer: shifting the focus from DNA to RNA. Proc. Natl. Acad. Sci. USA, 94: 952-955; 1997.
3. Helbing, C. C., Veillette, C., Riabowol, K., Johnston, R. N., and Garkavtsev, I. A novel candidate tumor suppressor, ING1, is involved in the regulation of apoptosis. Cancer Res., 57: 1255-1258, 1997.
4. Garkavtsev, I., and Riabowol, K. Extension of the replicative life span of human diploid fibroblasts by inhibition of the p33ING1 candidate tumor suppressor. Mol. Cell. Biol., 17: 2014-2019, 1997.
5. Gunduz, M., Ouchida, M., Fukushima, K., Hanafusa, H., Etani, T., Nishioka, S., Nishizaki, K., and Shimizu, K. Genomic structure of the human ING1 gene and tumor-specific mutations detected in head and neck squamous cell carcinomas. Cancer Res., 60: 3143-3146, 2000.
6. Saito, A., Furukawa, T., Fukushige, S., Koyama, S., Hoshi, M., Hayashi, Y., and Horii, A. p24/ING1-ALT1 and p47/ING1-ALT2, distinct alternative transcripts of p33/ING1. J. Hum. Genet., 45: 177-181, 2000.
7. Nagashima, M., Shiseki, M., Miura, K., Hagiwara, K., Linke, S. P., Pedeux, R., Wang, X. W., Yokota, J., Riabowol, K., and Harris, C. C. DNA damage-inducible gene p331NG2 negatively regulates cell proliferation through acetylation of p53. Proc. Natl. Acad. Sci. USA, 98: 9671-9676, 2001.
8. Gunduz, M., Ouchida, M., Fukushima, K., Ito, S., Jitsumori, Y., Nakashima, T., Nagai, N., Nishizaki, K., and Shimizu, K. Allelic loss and reduced expression of the ING3, a candidate tumor suppressor gene at 7q31, in human head and neck cancers. Oncogene, 21: 4462-4470, 2002.
9. Feng, X., Hara, Y., and Riabowol, K. Different HATS of the ING1 gene family. Trends Cell Biol., 12: 532-538, 2002.
10. Loewith, R., Meijer, M., Lees-Miller, S. P., Riabowol, K., and Young, D. Three yeast proteins related to the human candidate tumor suppressor p33(ING1) are associated with histone acetyltransferase activities. Mol. Cell. Biol., 20: 3807-3816, 2000.
11. Skowyra, D., Zeremski, M., Neznanov, N., Li, M., Choi, Y., Uesugi, M., Hauser, C. A., Gu, W., Gudkov, A. V., and Qin, J. Differential association of products of alternative transcripts of the candidate tumor suppressor ING1 with the mSin3/HDAC1 transcriptional corepressor complex. J. Biol. Chem., 276: 8734-8739, 2001.
12. Kuzmichev, A., Zhang, Y., Erdjument-Bromage, H., Tempst, P., and Reinberg, D. Role of the Sin3-histone deacetylase complex in growth regulation by the candidate tumor suppressor p33(ING1). Mol. Cell. Biol., 22: 835-848, 2002.
13. Vieyra, D., Loewith, R., Scott, M., Bonnefin, P., Boisvert, F. M., Cheema, P., Pastyryeva, S., Meijer, M., Johnston, R. N., Bazett-Jones, D. P., McMahon, S., Cole, M. D., Young, D., and Riabowol, K. Human ING1 proteins differentially regulate histone acetylation. J. Biol. Chem., 277: 29832-29839, 2002.
14. Leung, K. M., Po, L. S., Tsang, F. C., Siu, W. Y., Lau, A., Ho, H. T., and Poon, R. Y. The candidate tumor suppressor ING1b can stabilize p53 by disrupting the regulation of p53 by MDM2. Cancer Res., 62: 4890-4893, 2002.
15. Takahashi, M., Seki, N., Ozaki, T., Kato, M., Kuno, T., Nakagawa, T., Watanabe, K., Miyazaki, K., Ohira, M., Hayashi, S., Hosoda, M., Tokita, H., Mizuguchi, H., Hayakawa, T., Todo, S., and Nakagawara, A. Identification of the p33(ING1)-regulated genes that include cyclin B1 and proto-oncogene DEK by using cDNA microarray in a mouse mammary epithelial cell line NMuMG. Cancer Res., 62: 2203-2209, 2002.
16. Yasuda, H., Mizuno, A., Tamaoki, T., and Morinaga, T. ATBF1, a multiple-homeodomain zinc finger protein, selectively down-regulates AT-rich elements of the human α-fetoprotein gene. Mol. Cell. Biol., 14: 1395-1401, 1994.
17. Caruso, M. L., and Valentini, A. M. Overexpression of p53 in a large series of patients with hepatocellular carcinoma: a clinicopathological correlation. Anticancer Res., 19: 3853-3856, 1999.
18. Miura, Y., Tam, T., Ido, A., Morinaga, T., Miki, T., Hashimoto, T., and Tamaoki, T. Cloning and characterization of an ATBF1 isoform that expresses in a neuronal differentiation-dependent manner. J. Biol. Chem., 270: 26840-26848, 1995.
19. Ninomiya, T., Mihara, K., Fushimi, K., Hayashi, Y., Hashimoto-Tamaoki, T., and Tamaoki, T. Regulation of the α-fetoprotein gene by the isoforms of ATBF1 transcription factor in human hepatoma. Hepatology, 35: 82-87, 2002.
20. Lee, K. C., Crowe, A. J., and Barton, M. C. p53-mediated repression of α-fetoprotein gene expression by specific DNA binding. Mol. Cell. Biol., 19: 1279-1288, 1999.
21. Ogden, S. K., Lee, K. C., Wernke-Dollries, K., Stratton, S. A., Aronow, B., and Barton, M. C. p53 targets chromatin structure alteration to repress α-fetoprotein gene expression. J. Biol. Chem., 276: 42057-42062, 2001.
22. Khochbin, S., Verdel, A., Lemercier, C., and Seigneurin-Berny, D. Functional significance of histone deacetylase diversity. Curr. Opin. Genet. Dev., 11: 162-166, 2001.
23. Guarente, L. Sir2 links chromatin silencing, metabolism, and aging. Genes Dev., 14: 1021-1026, 2000.
24. Vaziri, H., Dessain, S. K., Ng Eaton, E., Imai, S. I., Frye, R. A., Pandita, T. K., Guarente, L., and Weinberg, R. A. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell, 107: 149-159, 2001.
25. Luo, J., Nikolaev, A. Y., Imai, S., Chen, D., Su, F., Shiloh, A., Guarente, L., and Gu, W. Negative control of p53 by Sir2α promotes cell survival under stress. Cell, 107: 137-148, 2001.
26. Smith, J. Human Sir2 and the 'silencing' of p53 activity. Trends Cell Biol., 12: 404-406, 2002.
27. Kataoka, H., Joh, T., Miura, Y., Tamaoki, T., Senoo, K., Ohara, H., Nomura, T., Tada, T., Asai, K., Kato, T., and Itoh, M. AT motif binding factor 1-A (ATBF1-A) negatively regulates transcription of the aminopeptidase N gene in the crypt-villus axis of small intestine. Biochem. Biophys. Res. Commun., 267: 91-95, 2000.
28. Nakabayashi, H., Koyama, Y., Sakai, M., Li, H. M., Wong, N. C., and Nishi, S. Glucocorticoid stimulates primate but inhibits rodent α-fetoprotein gene promoter. Biochem. Biophys. Res. Commun., 287: 160-172, 2001.
29. Beier, F., Taylor, A. C., and LuValle, P. The Raf-1/MEK/ERK pathway regulates the expression of the p21(Cip1/Waf1) gene in chondrocytes. J. Biol. Chem., 274: 30273-30279, 1999.
30. Morinaga, T., Yasuda, H., Hashimoto, T., Higashio, K., and Tamaoki, T. A human α-fetoprotein enhancer-binding protein, ATBF1, contains four homeodomains and seventeen zinc fingers. Mol. Cell. Biol., 11: 6041-6049, 1991.
31. Boland, D., Olineck, V., Bonnefin, P., Vieyra, D., Parr, E., and Riabowol, K. A panel of CAb antibodies recognize endogenous and ectopically expressed ING1 protein. Hybridoma., 19: 161-165, 2000.
32. Mendel, D. B., and Crabtree, G. R. HNF-1, a member of a novel class of dimerizing homeodomain proteins. J. Biol. Chem., 266: 677-680. 1991.
33. Nakabayashi, H., Hashimoto, T., Miyao, Y., Tjong, K. K., Chan, J., and Tamaoki, T. A position-dependent silencer plays a major role in repressing α-fetoprotein expression in human hepatoma. Mol. Cell. Biol., 11: 5885-5893, 1991.
34. el-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression. Cell, 75: 817-825, 1993.
35. Garkavtsev, I., Grigorian, I. A., Ossovskaya, V. S., Chernov, M. V., Chumakov, P. M., and Gudkov, A. V. The candidate tumour suppressor p331NG1 cooperates with p53 in cell growth control. Nature (Lond.), 391: 295-298, 1998.
36. Shiseki, M., Nagashima, M., Pedeux, R., Kitahama-Shiseki, M., Miura, K., Okamura, S., Onogi, H., Higashimoto, Y., Appella, E., Yokota, J., and Harris, C. C. p29ING4 and p281NG5 bind to p53 and p300, and enhance p53 activity. Cancer Res., 63: 2373-2378, 2003.
37. Vieyra, D., Toyama, T., Hara, Y., Boland, D., Johnston, R., and Riabowol, K. ING1 isoforms differentially affect apoptosis in a cell age-dependent manner. Cancer Res., 62: 4445-4452, 2002.
38. Zhang, C. C., Yang, J. M., Bash-Babula, J., White, E., Murphy, M., Levine, A. J., and Hait, W. N. DNA damage increases sensitivity to vinca alkaloids and decreases sensitivity to taxanes through p53-dependent repression of microtubule-associated protein 4. Cancer Res., 59: 3663-3670, 1999.
39. 2-M cell-cycle arrest. Int. J. Cancer, 88: 685-691, 2000.
40. Prives, C., and Manley, J. L. Why is p53 acetylated? Cell, 107: 815-818, 2001.
41. Lakin, N. D., and Jackson, S. P. Regulation of p53 in response to DNA damage, Oncogene, 18: 7644-7655, 1999.
42. Appella, E., and Anderson, C. W. Post-translational modifications and activation of p53 by genotoxic stresses. Eur. J. Biochem., 268: 2764-2772, 2001.
43. Sherr, C. J., and Weber, J. D. The ARF/p53 pathway. Curr. Opin. Genet. Dev., 10: 94-99, 2000.
44. Hoege, C., Pfander, B., Moldovan, G. L., Pyrowolakis, G., and Jentsch, S. RAD6-dependent DNA repair is linked to modification of PCNA by ubiquitin and SUMO. Nature (Lond.), 419: 135-141, 2002.
45. Aasland, R., Gibson, T. J., and Stewart, A. F. The PHD finger: implications for chromatin-mediated transcriptional regulation. Trends Biochem. Sci., 20: 56-59, 1995.
46. Hollstein, M., Rice, K., Greenblatt, M. S., Soussi, T., Fuchs, R., Sorlie, T., Hovig, E., Smith-Sorensen, B., Montesano, R., and Harris, C. C. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res., 22: 3551-3555, 1994.
47. Collier, J. D., Carpenter, M., Burt, A. D., and Bassendine, M. F. Expression of mutant p53 protein in hepatocellular carcinoma. Gut., 35: 98-100, 1994.
48. Livni, N., Eid, A., Ilan, Y., Rivkind, A., Rosenmann, E., Blendis, L. M., Shouval, D., and Galun, E. p53 expression in patients with cirrhosis with and without hepatocellular carcinoma. Cancer (Phila.), 75: 2420-2426, 1995.
49. Edis, C., Kahler, C., Klotz, W., Herold, M., Feichtinger, H., Konigsreiner, A., Margreiter, R., Jaschke, W., and Vogel, W. A comparison between α-fetoprotein and p53 antibodies in the diagnosis of hepatocellular carcinoma. Transplant. Proc., 30: 780-781, 1998.
50. Toyama, T., Iwase, H., Watson, P., Muzik, H., Saettler, E., Magliocco, A., DiFrancesco, L., Forsyth, P., Garkavtsev, I., Kobayashi, S., and Riabowol, K. Suppression of ING1 expression in sporadic breast cancer. Oncogene, 18: 5187-5193, 1999.
51. Oki, E., Maehara, Y., Tokunaga, E., Kakeji, Y., and Sugimachi, K. Reduced expression of p33(ING1) and the relationship with p53 expression in human gastric cancer. Cancer Lett., 147: 157-162, 1999.
52. ING1 in hepatocellular carcinoma: relationships to tumor differentiation and cyclin E kinase activity. Scand. J. Gastroenterol., 37: 1440-1448, 2002.